title: AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions.
authors.forename: C
authors.initials: C
authors.lastname: Haferlach
authors.forename: F
authors.initials: F
authors.lastname: Dicker
authors.forename: A
authors.initials: A
authors.lastname: Kohlmann
authors.forename: S
authors.initials: S
authors.lastname: Schindela
authors.forename: T
authors.initials: T
authors.lastname: Weiss
authors.forename: W
authors.initials: W
authors.lastname: Kern
authors.forename: S
authors.initials: S
authors.lastname: Schnittger
authors.forename: T
authors.initials: T
authors.lastname: Haferlach
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D002871:Chromosome Banding; D017353:Gene Deletion; D020869:Gene Expression Profiling; D015321:Gene Rearrangement; D011905:Genes, ras / Q000235:genetics*; D005838:Genotype; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000473:pathology; D025542:Neurofibromin 1 / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide
chemical_list: D014408:Biomarkers, Tumor; C095514:CBFbeta-MYH11 fusion protein; D025542:Neurofibromin 1; D015514:Oncogene Proteins, Fusion